Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market

Core Insights - Autonomix Medical, Inc. is set to initiate a follow-on phase ("PoC 2") of its proof-of-concept trial, focusing on the safety and effectiveness of transvascular energy delivery to alleviate cancer pain, with the expansion phase expected to start in Q2 2025 [2][3][4] Company Overview - Autonomix is a medical device company dedicated to advancing innovative technologies for diagnosing and treating diseases related to the nervous system [7][8] - The company's technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [7] Market Expansion - The follow-on PoC 2 phase aims to evaluate additional visceral cancers, potentially doubling the addressable market beyond pancreatic cancer pain, by including gall bladder, liver, and bile duct cancers [3][4] - The initial phase (PoC 1) demonstrated significant pain reduction and decreased opioid use in patients with severe pancreatic cancer pain, leading to the decision to expand the investigation [4][5] Technology and Applications - Autonomix's technology is positioned as a platform capable of addressing various indications, including cardiology, hypertension, and chronic pain management, with a concentrated focus on interventional cancer pain management applications [5][8] - The company has established key opinion leader relationships and emerging preclinical evidence to support further expansion in oncology and gastroenterology sectors [5]